Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer
These updated analyses were the first to unveil the 5-year survival benefits of neoadjuvant sintilimab monotherapy, implying the potential value of PD-1 inhibitors in neoadjuvant therapy.
Authors
- Fang Lv (ORCID: https://orcid.org/0000-0002-1872-781X)
- Bolun Zhou (ORCID: https://orcid.org/0000-0001-8143-4852)
- Shugeng Gao (ORCID: https://orcid.org/0000-0003-1888-2622)
- Kang Shao (ORCID: https://orcid.org/0000-0001-5779-8840)
- Bin Qiu (ORCID: https://orcid.org/0000-0001-6466-3979)
- Wei Guo (ORCID: https://orcid.org/0000-0001-8302-8292)
- Ning Li (ORCID: https://orcid.org/0000-0002-3945-2536)
- Jian Li (ORCID: https://orcid.org/0000-0002-4549-0694)
- Fan Zhang (ORCID: https://orcid.org/0009-0002-8365-3340)
- Qi Xue (ORCID: https://orcid.org/0000-0002-5086-4654)
- Liang Zhao (ORCID: https://orcid.org/0000-0003-3608-4915)
- Shuhang Wang (ORCID: https://orcid.org/0000-0001-5753-5936)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1136/jitc-2024-009355
- Citations
- 8
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.35
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine